Other Health

Insights on the Mycoplasma Testing Market 2020-2024: COVID-19 Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024 - Technavio

Thursday, December 3, 2020 - 1:50pm

Based on the product, the consumables segment is expected to witness lucrative growth during the forecast period.

Key Points: 
  • Based on the product, the consumables segment is expected to witness lucrative growth during the forecast period.
  • By geography, North America is going to have a lucrative growth during the forecast period.
  • About 40% of the markets overall growth is expected to originate from North America.
  • The US is a key market for mycoplasma testing in North America.

Online Doctor Consultation Market 2020-2024- Featuring American Well Corp., Dictum Health Inc., among others to contribute to the market growth | Industry Analysis, Market Trends, Opportunities, and Forecast 2024

Thursday, December 3, 2020 - 1:20pm

The online doctor consultation market is poised to grow by USD 3.80 bn during 2020-2024, progressing at a CAGR of over 7% during the forecast period.

Key Points: 
  • The online doctor consultation market is poised to grow by USD 3.80 bn during 2020-2024, progressing at a CAGR of over 7% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201203005543/en/
    Technavio has announced its latest market research report titled Global Online Doctor Consultation Market 2020-2024 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your Business?
  • The report on the online doctor consultation market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The online doctor consultation market analysis includes product segment and geography landscape.

 Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures

Thursday, December 3, 2020 - 1:30pm

Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round.

Key Points: 
  • Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round.
  • The round was led by Khosla Ventures, with participation from Longevity Fund, Refactor Capital, Shanda and additional investors.
  • Rubedo has made remarkable progress and this seed investment will accelerate development of their clinical pipeline, said Vinod Khosla, founder of Khosla Ventures.
  • Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases.

UHSM Health Share Partners with Relevant Magazine to Further the Message of Faith in Workplace

Thursday, December 3, 2020 - 1:00pm

We are pleased to offer the latest digital issue of Relevant Magazine at no cost to the wider public, said Christopher Jin, president of UHSM.

Key Points: 
  • We are pleased to offer the latest digital issue of Relevant Magazine at no cost to the wider public, said Christopher Jin, president of UHSM.
  • As faith continues to transcend across the world, faith in business and the workplace is becoming increasingly prevalent.
  • Along with Relevant Magazine partnership, UHSM has launched several community initiatives nationwide, continuing faith in business.
  • UHSM (Unite Health Share Ministries) is a nonprofit, faith-based health sharing ministry that facilitates member-to-member health sharing among fellow Christians, serving as a connector to administer medical cost sharing.

Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

Thursday, December 3, 2020 - 1:30pm

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately.
  • Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent.
  • From 2010 to 2012, Mr. Shepard served as president and chief executive officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc. (acquired by Pfizer Inc.).
  • Mr. Shepard currently serves on the board of directors of Inovio Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Craig Hospital and is chair of the board of directors for the Christopher & Dana Reeve Foundation.

New Coalition Aims To Close The Opportunity Gap In Bioscience

Thursday, December 3, 2020 - 1:00pm

To address these gaps in the life sciences sector, BIIG brings together leaders with a range of industry perspectives including R&D, commercialization, human capital, venture investing and corporate governance.

Key Points: 
  • To address these gaps in the life sciences sector, BIIG brings together leaders with a range of industry perspectives including R&D, commercialization, human capital, venture investing and corporate governance.
  • Diverse teams strengthen companies and spur innovation, yet minorities are historically underfunded as entrepreneurs and underrepresented in startup leadership.
  • It is vital for the life sciences sector to become more inclusive and focus on solutions that accelerate change.
  • The participants are committed to change and will share proven practices to develop solutions for the entire sector.

i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon

Thursday, December 3, 2020 - 1:00pm

i2O Therapeutics , an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures , the corporate venture fund of Colorcon Inc.

Key Points: 
  • i2O Therapeutics , an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures , the corporate venture fund of Colorcon Inc.
  • In addition to this investment, Colorcon will collaborate with i2O to accelerate i2Os research and development efforts.
  • We welcome Colorcon Ventures as a strategic investor at this pivotal time of company growth, said Ravi Srinivasan, Ph.D., Chief Executive Officer of i2O Therapeutics.
  • Colorcon Ventures strategic focus on technologies that transform conventional delivery pathways aligns well with i2O.

Lake of the Woods District Hospital Prepares for Future Smart Hospital with Vocera Solutions

Thursday, December 3, 2020 - 1:02pm

Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Lake of the Woods District Hospital (LWDH) in Kenora, Ontario is deploying intelligent communication solutions from Vocera to help protect and connect care teams now and beyond COVID-19.

Key Points: 
  • Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Lake of the Woods District Hospital (LWDH) in Kenora, Ontario is deploying intelligent communication solutions from Vocera to help protect and connect care teams now and beyond COVID-19.
  • Among those solutions are the wearable, voice-controlled Vocera Smartbadge and the Vocera Vina smartphone application.
  • Vocera is proud to support Lake of the Woods District Hospital and its mission to build a fully-integrated smart hospital of the future, said Brent Lang, President and CEO of Vocera.
  • Vocera and the Vocera logo are trademarks of Vocera Communications, Inc. registered in the United States and other jurisdictions.

BAT launches VapeExplained.com

Thursday, December 3, 2020 - 12:26pm

The BAT Group (BAT) has today launched VapeExplained.com , a digital information hub providing adult smokers and vapers with factual answers to the questions most commonly searched for online.

Key Points: 
  • The BAT Group (BAT) has today launched VapeExplained.com , a digital information hub providing adult smokers and vapers with factual answers to the questions most commonly searched for online.
  • The site launches at a time when smokers and vapers face increasing challenges to find clear and balanced information regarding vaping.
  • BAT encourages those who otherwise continue to smoke, to switch completely to scientifically-substantiated, reduced-risk alternatives.
  • BAT is committed to building A Better Tomorrow by reducing the health impact of our business.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

Thursday, December 3, 2020 - 1:00pm

Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.

Key Points: 
  • Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.
  • We believe that QPX7728 has demonstrated a preclinical profile that exceeds that of recently marketed beta-lactamase inhibitors, as well as those in ongoing clinical trials.
  • Beta-lactamases are bacterial enzymes that destroy beta-lactam antibiotics and are the major mechanism of resistance to these drugs in gram-negative bacteria.
  • Qpex has a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.